Loïc Ysebaert
YOU?
Author Swipe
View article: Overall survival outcomes with first‐line continuous ibrutinib and fixed‐duration ibrutinib‐venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age‐matched European population
Overall survival outcomes with first‐line continuous ibrutinib and fixed‐duration ibrutinib‐venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age‐matched European population Open
View article: Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group Open
Brexucabtagene autoleucel (brexu-cel) is the anti-CD19 CAR-T therapy approved for the treatment of relapse/refractory (RR) mantle cell lymphoma (MCL). Our study, conducted in the scope of the french DESCAR-T registry, aimed to analyze outc…
View article: Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia
Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia Open
Achieving complete response/remission (CR) by International Workshop on Chronic Lymphocytic Leukemia 2018 criteria indicates complete remission of leukemia in all disease compartments. We evaluated CR rate as a surrogate endpoint for progr…
View article: Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA
Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA Open
In this large real-world cohort of newly diagnosed DLBCL patients, age, occupational status, and patients' pathway were linked to very long delays to treatment. Interventions to streamline DTIs, especially for older and/or blue-collar or f…
View article: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS) Open
View article: OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL
OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL Open
View article: 886 | RETURN TO NORM AFTER LYMPHOMA CHEMOTHERAPY: SOCIAL, PSYCHOLOGICAL AND BIOLOGICAL DETERMINANTS OF ALTERED QUALITY OF LIFE
886 | RETURN TO NORM AFTER LYMPHOMA CHEMOTHERAPY: SOCIAL, PSYCHOLOGICAL AND BIOLOGICAL DETERMINANTS OF ALTERED QUALITY OF LIFE Open
View article: 245 | EFFICACY AND TOLERANCE OF CAR T‐CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: ANALYSIS FROM THE FRENCH DESCAR‐T REGISTRY
245 | EFFICACY AND TOLERANCE OF CAR T‐CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: ANALYSIS FROM THE FRENCH DESCAR‐T REGISTRY Open
View article: Time-series RNA-Seq and data-driven network inference unveil dynamics of cell activation, survival and crosstalk in Chronic Lymphocytic Leukaemia in vitro models
Time-series RNA-Seq and data-driven network inference unveil dynamics of cell activation, survival and crosstalk in Chronic Lymphocytic Leukaemia in vitro models Open
How do cancer cells respond to their environment, and what are the key regulators behind their behaviour? While immune cell reprogramming in the tumour microenvironment (TME) has been extensively studied, the dynamic regulatory changes wit…
View article: Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the <scp>LYSA</scp> group
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the <span>LYSA</span> group Open
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax …
View article: Time-series RNA-Seq and data-driven network inference unveil dynamics of cell activation, survival and crosstalk in Chronic Lymphocytic Leukaemia <i>in vitro</i> models
Time-series RNA-Seq and data-driven network inference unveil dynamics of cell activation, survival and crosstalk in Chronic Lymphocytic Leukaemia <i>in vitro</i> models Open
How do cancer cells respond to their environment, and what are the key regulators behind their behaviour? While immune cell reprogramming in the tumour microenvironment (TME) has been extensively studied, the dynamic regulatory changes wit…
View article: Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA Open
View article: Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France Open
Malignant histiocytoses (MH) are rare and poorly understood cancers, with no established therapeutic guidelines. We conducted a national retrospective study of MH diagnosed in France between 2000 and 2023. All cases underwent centralized h…
View article: Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension
Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension Open
Objective: Ibrutinib has been the first Bruton tyrosine kinase inhibitor (BTKi) authorized for the treatment of B-cell lymphoproliferative disorders (B-LPDs). Numerous publications have confirmed the efficacy of this orally administrated d…
View article: The CLL hunters: finally, BTK got arrested
The CLL hunters: finally, BTK got arrested Open
International audience
View article: Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL Open
In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using t…
View article: Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial Open
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorub…
View article: New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling
New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling Open
Background One of the first clinical observations of ibrutinib activity in the treatment of chronic lymphocytic leukemia (CLL) is a rapid decline in lymph nodes size. This phenomenon is accompanied by an hyperlymphocytosis, either transien…
View article: Integrated spatial and multimodal single‐cell transcriptomics reveal patient‐dependent cell heterogeneity in splenic marginal zone lymphoma
Integrated spatial and multimodal single‐cell transcriptomics reveal patient‐dependent cell heterogeneity in splenic marginal zone lymphoma Open
Biological hallmarks of splenic marginal zone lymphoma (SMZL) remain poorly described. Herein, we performed in‐depth SMZL characterization through multimodal single‐cell analyses of paired blood/spleen samples. The 3’‐single‐cell RNA‐seque…
View article: Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?
Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life? Open
Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T‐cell therapy. We prospectively a…
View article: Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress Open
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with relapsed/refractory B-cell derived hematologic malignancies. To date, six CAR T-cell therapies, targeting either CD19 or B-cell maturation antigen, ha…
View article: Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Results of the EpiRCHOP Phase II Study on the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Patients Newly Diagnosed with Diffuse Large B Cell Lymphoma: A LYSA Study
Results of the EpiRCHOP Phase II Study on the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Patients Newly Diagnosed with Diffuse Large B Cell Lymphoma: A LYSA Study Open
View article: Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial Open
View article: Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort Open
Real-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective noninterventional multicentric coh…
View article: Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine Open
Background Follicular lymphoma (FL), the most common indolent non-Hodgkin’s Lymphoma, is a heterogeneous disease and a paradigm of the contribution of immune tumor microenvironment to disease onset, progression, and therapy resistance. Pat…
View article: S141: INHIBITION OF MYC TRANSLATION THROUGH TARGETING OF THE NEWLY IDENTIFIED PHB-EIF4F COMPLEX AS THERAPEUTIC STRATEGY INCHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S141: INHIBITION OF MYC TRANSLATION THROUGH TARGETING OF THE NEWLY IDENTIFIED PHB-EIF4F COMPLEX AS THERAPEUTIC STRATEGY INCHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Open
Background: CLL is the most common type of leukemia in adult, and despite great advance in the standard of care in the last decades, there is still no cure available. CLL cells are dependent on their microenvironment for proliferation and …
View article: P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE? Open
Topic: 35. Quality of life and palliative care Background: CD19 CAR-T cells have been approved for the treatment of relapse/refractory (R/R) lymphoma. Although CAR T-cells are able to induce prolonged remission (and potentially cure) in a …
View article: P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Open
Background: MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a key component of the CARD11-BCL10-MALT1 (CBM) complex, which activates the classical NF-κB pathway. JNJ-67856633, a highly selective protease inhib…
View article: Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia Open
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is widely used for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL). A prominent effect of ibrutinib is to disrupt the retention of CL…